Adolquir is applied across domains where additional symptomatic support is needed, with the ability to provide symptomatic relief against symptoms related to inflammatory or irritative states. Its use is focused on providing supportive assistance in clinical settings marked by heightened patient discomfort. The medication is used for the short-term management of mild to moderate pain.

Therapeutic Support

The medication is relevant for managing symptoms that interfere with daily comfort, such as those arising from musculoskeletal pain (like sprains and strains), dental discomfort, pain and swelling following surgical procedures, and intense, cyclical manifestations like primary dysmenorrhoea. The medication is applied in addressing symptoms related to inflammatory or irritative states (pain and localized swelling), which generally contributes to easing the overall symptom load during symptomatic periods. It may assist with managing symptoms associated with recurrent or episodic manifestations, supporting the patient during difficult episodes by easing distress.

Quick Fact: Relief for Acute Pain

The medication is considered relevant in contexts involving heightened systemic burden, providing support that helps ease the overall symptom burden.

Eligibility Map: Who Can and Cannot Use Adolquir — Official Regulatory Information

Eligibility Classifications (High-Level)

Connection to the overall eligibility profile

Regulatory documents define eligibility by setting absolute prohibitions for patients with severe underlying conditions, such as severe heart, liver, or kidney failure, active GI disease, or a known NSAID allergy. Use is not recommended for the pediatric population due to a lack of established safety data. Furthermore, the medicine is contraindicated during the third trimester of pregnancy and while breastfeeding. For older adults and those with mild organ impairment, use is conditional and mandates special caution and close monitoring.

Interactions with other medicines and products

Adolquir (dexketoprofen trometamol) has official regulatory restrictions and cautions regarding its co-administration with numerous substances, primarily due to its classification as a Non-Steroidal Anti-Inflammatory Drug (NSAID).

Interaction Classifications

Official Interaction Statements

• Pharmacodynamic Risk: Co-administration with anticoagulants, oral corticosteroids, antiplatelet agents, or SSRIs may lead to a clinically significant increased risk of bleeding or haemorrhage, an additive effect documented in regulatory labels.
• Exposure Alterations: Dexketoprofen may increase the plasma levels of certain co-administered drugs, including Lithium and Methotrexate, due to interference with their clearance or renal excretion.
• Renal Impairment Risk: The use of Adolquir with diuretics, ACE inhibitors, or Angiotensin II Receptor Antagonists may reduce their efficacy and increase the likelihood of nephrotoxicity.
• Timing Requirement: Regulatory information advises taking oral Adolquir at least 30 minutes before meals when treating acute pain, as food is documented to delay the rate of absorption.
• Population Note: Official labeling identifies elderly patients and those with hypovolaemia as having an increased susceptibility to severe interaction-related adverse effects, necessitating close monitoring.

The overall interaction structure, as defined by government regulatory documents, centers on managing pharmacodynamic risks—like increased bleeding potential—and addressing pharmacokinetic issues, specifically the reduced elimination of certain co-administered drugs and the delay in absorption caused by food.

How Adolquir Works

Adolquir's mechanism of action operates at the enzymatic level within the arachidonic acid cascade. Its active component, dexketoprofen, acts primarily as a non-selective inhibitor of the cyclo-oxygenase (COX) enzymes, specifically targeting both the COX-1 and COX-2 isoforms. This interaction is classified as enzyme-mediated signaling inhibition.

Inhibition of COX prevents the catalytic conversion of arachidonic acid into various lipid signaling molecules, most notably the prostaglandins and thromboxanes. This action modifies early molecular steps in the cascade by reducing the intracellular synthesis and subsequent release of these specific mediators. The resulting decrease in pro-inflammatory and pain-sensitizing mediators initiates alterations in systemic signaling processes.

This mechanism mediates pathway function through direct enzyme binding, resulting in a quantifiable change to local biochemical activity. The overall consequence is a system-level physiological modulation involving the regulation of processes driven by these signaling patterns, without addressing any specific condition or therapeutic outcome.

Adolquir is administered under strict regulatory guidelines for short-term symptomatic use, utilizing multiple dosage forms to address varying clinical needs. The approved routes of administration include oral use, via either tablets or granules for solution, and parenteral use, which involves intramuscular (IM) injection or intravenous (IV) bolus or slow infusion.

Usage patterns are defined by these limits and must adhere to specific contextual requirements. Oral administration for acute relief should occur at least 30 minutes before meals to ensure optimal speed of action. The injectable formulation is strictly limited to a maximum of two consecutive days, after which a transition to oral treatment is mandated. For patient populations with altered metabolism, including older adults and those with mild renal or hepatic impairment, the total daily dose must be reduced to a maximum of 50 mg.

Parenteral administration also requires precise handling. IV infusion solutions must be prepared by dilution, protected from natural daylight, and infused slowly over a period of 10 to 30 minutes. An IV bolus, conversely, is administered over no less than 15 seconds. These administration rules ensure the medicine is used within the standardized therapeutic and procedural framework.

Research Evidence / Overview of Studies for Adolquir

Evidence for Use in Acute Postoperative Pain

Research exploring the use of Adolquir for pain following surgical procedures, such as dental extractions or orthopedic operations, has primarily been conducted using Randomized Controlled Trials (RCTs) and systematic reviews. These trials were applied in studies examining patient-reported experiences of moderate-to-severe pain. Researchers monitored outcomes related to physical discomfort, often measuring pain intensity and the patient's need for additional pain relief. Findings describe patterns observed in the studies related to a rapid onset of measured symptom changes. Separately, research explored the co-administration of Adolquir alongside opioid pain relievers, and studies monitored whether this approach was associated with changes in the overall amount of opioid medication required.

The majority of this evidence is derived from studies observing responses over defined time intervals, meaning the follow-up durations were limited. Most consistent data cover the first few hours up to two days following administration. There is limited information for long-term outcomes for continuous pain management extending beyond the immediate post-operative period.

Evidence for Use in Acute Musculoskeletal Pain

Adolquir was evaluated in research exploring physical discomfort associated with conditions involving periods of heightened symptoms like acute sprains, strains, and low back pain. The evidence is largely based on short-term RCTs that focused on episodes where symptoms become more noticeable due to acute injury. Research highlights changes measured during the study period, indicating patterns related to the speed of the measured symptom changes in the observed adult populations.

A key limitation is that these studies focused on short-term symptom changes over days. The results apply only to the populations studied during the immediate acute phase. Research does not provide insight into whether an individual will respond similarly over extended periods, as the long-term effects are not fully established for chronic musculoskeletal conditions.

Evidence in Specific Patient Groups

The majority of formal clinical research has been conducted in adult patients experiencing acute pain. Data for certain groups remain insufficient, such as those with pre-existing health conditions or compromised organ function, and for older adults. Regulatory information acknowledges that these groups may exhibit different physiological responses. Therefore, the results apply only to the populations studied in the trials.

Common questions about Adolquir (FAQ)

Q: Can I split the Adolquir tablet to get a lower dose?

According to the official product information, certain tablet forms of this medicine feature a score line, or break-mark. This mark indicates that the tablet is designed to be divided into equal doses. The availability of a score line facilitates flexible dosing as determined by a healthcare professional.

Q: Is Adolquir suitable for a minor headache?

Official regulatory documents indicate that Adolquir is specifically authorized for the short-term treatment of acute pain that is classified as mild to moderate in intensity. This includes pain associated with musculoskeletal issues, dental procedures, and menstrual periods (dysmenorrhoea). Minor headaches are not one of the specific conditions explicitly listed in the authorized uses.

Q: How long does the pain relief from one dose of Adolquir last?

Studies and official information indicate that the analgesic (pain-relieving) effect of a single dose of Adolquir is based on clinical data. Regulatory documents state that the pain relief is generally reported to persist for approximately four to six hours following administration.

How to Store and Dispose of Adolquir

Adolquir (dexketoprofen trometamol) must be stored strictly according to the official regulatory instructions to maintain its integrity.

Required Storage Conditions

The tablets should be stored at or below 30 C for specific packaging types. The medicine must be kept in the original outer carton and blister to ensure it is protected from light. As a mandatory safety requirement, Adolquir must be secured out of the sight and reach of children at all times.

Official Disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements for pharmaceutical waste. Do not dispose of Adolquir in household trash or wastewater (sewer systems).